Altimmune
ALT
16 hedge funds and large institutions have $867K invested in Altimmune in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 14 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
13.5% more ownership
Funds ownership: 0.28% → 13.79% (+14%)
34% less capital invested
Capital invested by funds: $1.32M → $867K (-$451K)
36% less funds holding
Funds holding: 25 → 16 (-9)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
93% less call options, than puts
Call options by funds: $3K | Put options by funds: $44K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.01M |
| 2 |
Renaissance Technologies
New York
|
+$179K |
| 3 |
Morgan Stanley
New York
|
+$93.3K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$75.3K |
| 5 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$123K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$62K |
| 3 |
Bank of New York Mellon
New York
|
-$30K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | +$250 | +23 | New |
|
ALT Hedge Fund Activity: Q3 2018 in Review
16 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2018, worth a combined $867K — down 34% from $1.32M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ALT and 5 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 5 added.
The largest buyer was CVI Holdings, opening a new position worth an estimated $1.01M. The largest seller was Vanguard Group, exiting entirely with an estimated $123K sold.
- 16 institutional investors held Altimmune (ALT) as of Q3 2018, down from 25 in Q2 2018.
- Funds reported $867K of Altimmune stock for Q3 2018, down 34% quarter-over-quarter.
- 5 funds opened new Altimmune positions in Q3 2018 and 14 closed out, a net change of -9 holders.
- The largest Altimmune buyer in Q3 2018 was CVI Holdings, an estimated $1.01M added.
- The largest Altimmune seller in Q3 2018 was Vanguard Group, an estimated $123K sold.
Based on aggregated 13F filings for Q3 2018.